Nephron Loss And Systemic Risk: An Overview Of Chronic Kidney Disease

Abstract

Persistent abnormalities in urine, abnormalities in structure, or reduced excretory renal function suggestive of a loss of functional nephrons are the hallmarks of chronic kidney disease. The mainstays of therapy are blood pressure regulation, renin-angiotensin system inhibition, and disease-specific therapies. Diagnosis and therapy are necessary for CKD consequences that impact cardiovascular health and quality of life, such as anemia, metabolic acidosis, and secondary hyperparathyroidism. GFR, which can be approximated using equations or evaluated using exogenous markers like DTPA and iohexol, is the best biomarker of total renal function currently available. A higher chance of CKD development and death is linked to the presence of proteinuria. Renal biopsy specimens can provide conclusive proof of chronic kidney disease by exhibiting typical modifications such interstitial fibrosis, tubular atrophy, and glomerular sclerosis. Among the complications include iron insufficiency, decreased red blood cell survival, and anemia brought on by the kidney's decreased production of erythropoietin. Mineral bone disease is brought on by abnormalities in the metabolism of calcium, phosphate, and vitamin D. Individuals with chronic kidney disease (CKD) have a five to ten times higher risk of dying before reaching the terminal stages of the disease.